Type 1 diabetes confers a cardiovascular burden that is often obscured by the young age of affected individuals and by the ...

Conclusions Rosiglitazone was associated with a significant increase in the risk of myocardial infarction and with an increase in the risk of death from cardiovascular causes that had borderline ...

The primary end point event (composite of death from CV causes, myocardial infarction, or stroke) occurred in 12.2 and 13.1% in the tirzepatide and dulaglutide groups, respectively. HealthDay News — ...

An appropriate duration of dual antiplatelet therapy after percutaneous coronary intervention for acute myocardial infarction that has been treated with guideline-recommended complete ...

Tirzepatide was noninferior to dulaglutide for the primary endpoint of time to first occurrence of death from cardiovascular causes, myocardial infarction, or stroke. Topline data were announced from ...

Prior stroke and neurological disability increased long-term mortality after myocardial infarction. Learn how neurological status may guide risk assessment.

Tirzepatide noninferior to dulaglutide with respect to composite of death from cardiovascular causes, myocardial infarction, or stroke. (HealthDay News) — Tirzepatide is noninferior to dulaglutide ...